Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (Nasdaq: VKTX) is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its lead candidate, VK2735, is a dual GLP-1 and GIP receptor agonist in oral and subcutaneous formulations for potential treatment of obesity and other metabolic disorders;… From the company’s description.
In fiscal 2025, Viking Therapeutics, Inc. reported revenue of $0.00M and a net loss of $359.64M. Operations used $278.69M in cash. Over the twelve months to Jun 30, 2026, revenue was $0.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Viking Therapeutics, Inc. does
In the company’s own words
Viking Therapeutics, Inc. (Nasdaq: VKTX) is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its lead candidate, VK2735, is a dual GLP-1 and GIP receptor agonist in oral and subcutaneous formulations for potential treatment of obesity and other metabolic disorders; subcutaneous Phase 3 studies are underway, following positive Phase 2 results for both formulations. Other programs include VK2809, an oral selective thyroid hormone receptor beta agonist studied for fatty liver disease and metabolic disorders; VK0214, a similar agonist being developed for X-linked adrenoleukodystrophy; and VK5211, an oral selective androgen receptor modulator studied for recovery after hip fracture. The company also has a preclinical dual amylin and calcitonin receptor agonist program for obesity. Viking is focused on research and clinical development rather than marketing approved medicines, and it is pursuing potential licensing or partnering opportunities for VK0214 and VK5211. Its website is https://www.vikingtherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1607678
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Viking Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Viking Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Viking Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Viking Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Viking Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”